Skip to content
medxy logo Medxy AI
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • Specialties
    • Allergy & Immunology
    • Anesthesiology
    • Cardiology
    • Critical Care
    • Dermatology
    • Diabetes & Endocrinology
    • Emergency Medicine
    • Family Medicine & Nutrition
    • Gastroenterology
    • General Surgery
    • Hematology-Oncology
    • HIV/AIDS
    • Infectious Diseases
    • Internal Medicine
    • Nephrology
    • Neurology
    • Nursing & care
    • OB/GYN & Women’s Health
    • Oncology
    • Ophthalmology
    • Orthopedics
    • Otorhinolaryngology
    • Pathology & Lab Medicine
    • Pediatrics
    • Plastic Surgery
    • Psychiatry
    • Public Health
    • Radiology
    • Respiratory
    • Rheumatology
    • Urology
  • Clinical Updates
  • Medical News
  • iDoctor
  • facebook.com
  • twitter.com
  • t.me
  • instagram.com
  • youtube.com
Subscribe

pediatric ALL

  • Home
  • pediatric ALL
Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring
Posted inHematology-Oncology news Pediatrics

Genomic Fusion Breakpoints: A Breakthrough in Pediatric ALL MRD Monitoring

Posted by MedXY By MedXY 04/24/2026
A novel genomic fusion breakpoint (GFB)-based MRD monitoring approach demonstrates superior sensitivity and specificity in pediatric ALL, addressing limitations of current IG/TCR-based methods, particularly in ETV6::RUNX1- and MEF2D-rearranged subtypes.
Read More
Withholding Two Daunorubicin Doses in Induction Preserves Outcomes and Lowers Fungal Risk in Favorable-Risk Pediatric B-ALL
Posted inHematology-Oncology news Pediatrics

Withholding Two Daunorubicin Doses in Induction Preserves Outcomes and Lowers Fungal Risk in Favorable-Risk Pediatric B-ALL

Posted by MedXY By MedXY 12/08/2025
In children with favorable B-lineage ALL, omission of two daunorubicin doses late in induction was noninferior for 5-year EFS and OS and associated with fewer invasive fungal infections, supporting reduced anthracycline exposure in selected low-risk patients.
Read More
  • Chronic Kidney Disease Worsens Short-Term Outcomes in Hospitalized Patients With Cirrhosis Across a Global Cohort
  • Computer-Aided Detection Increased Adenoma Detection in a Large Pragmatic Cluster Randomized Colonoscopy Study
  • Ultra-High-Resolution Photon-Counting CTA Improves Noninvasive Detection of Neurovascular In-Stent Restenosis
  • Neurocognitive Outcomes of In Utero Exposure to Antiseizure Medication: An Australian Cohort Study
  • A Two-Marker Plasma Model Closely Mirrors PET-Based Biological Staging of Alzheimer Disease
  • About us
  • Contact us
  • MedXY story
  • Privacy Policy
  • Subscribe Now!
  • 账号

  • English
  • 日本語
  • Tiếng Việt
  • 中文

Alzheimer's disease artificial intelligence atrial fibrillation biomarkers breast cancer Cardiology cardiovascular disease cardiovascular risk chronic kidney disease clinical trial clinical trials critical care depression diabetes epidemiology health heart failure Hypertension immunotherapy inflammation MASLD mental health metformin Mortality myocardial infarction nutrition obesity older adults oncology Pediatrics precision medicine Pregnancy prevention prostate cancer public health randomized clinical trial randomized trial risk stratification SGLT2 inhibitors stroke targeted therapy type 1 diabetes type 2 diabetes weight loss women's health

Your health, we care

Copyright 2026 — Medxy AI. All rights reserved.
Scroll to Top
Sign in